Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 9 , ISSUE 1 ( January-June, 2019 ) > List of Articles


Update on Liver Transplantation: What is New Recently?

Sinan Akosman, Merve Gurakar

Keywords : Direct-acting antiviral drugs, Donor pool, Highly active antiretroviral therapy, Liver transplantation, Scoring system, Severe alcoholic hepatitis

Citation Information : Akosman S, Gurakar M. Update on Liver Transplantation: What is New Recently?. Euroasian J Hepatogastroenterol 2019; 9 (1):34-39.

DOI: 10.5005/jp-journals-10018-1293

License: CC BY-NC 4.0

Published Online: 01-09-2019

Copyright Statement:  Copyright © 2019; The Author(s).


Liver transplantation (LT) is an evolving area of medicine for the treatment of certain types of malignancies and acute and chronic liver failures. Since the topic is evolving, new literature is increasingly available. In recent years, with the emerging potent antiviral therapies, hepatitis C virus-infected patients have successful patient and graft survival outcomes. Even human immunodeficiency virus (HIV) positive patients previously contraindicated for organ transplantation are transplanted with comparable outcomes. With increasing demand for LT, the shortage of the donor pool became the rate limiting factor in this hopeful treatment. To overcome waitlist mortality and expand the donor pool, scoring systems have been modified and organs from HIV and/or hepatitis C infected donors are now accepted, under certain circumstances. The new literature also questions the 6-month alcohol abstinence rule for the transplantation of alcoholic liver disease (ALD), in light of early transplantation results from severe alcoholic hepatitis (SAH) trials.

PDF Share
  1. Merion RM, Schaubel DE, et al. The survival benefit of liver transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005;5(2):307-313.
  2. Freeman RB, Wiesner RH, et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004;10(1):7-15.
  3. Thuluvath PJ, Guidinger MK, et al. Liver transplantation in the United States, 1999-2008. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2010;10(4 Pt 2):1003-1019.
  4. Northup PG, Intagliata NM, et al. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology 2015;61(1):285-291.
  5. Bhat M, Ghali P, et al. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics. J Hepatol 2017;66(2):374-381.
  6. Heuman DM, Abou-Assi SG, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40(4):802-810.
  7. Londono MC, Guevara M, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130(4):1135-1143.
  8. Dawwas MF, Lewsey JD, et al. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007;13(8):1115-1124.
  9. Leise MD, Yun BC, et al. Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transpl 2014;20(6):687-697.
  10. Yun BC, Kim WR, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009;49(5):1610- 1615.
  11. Hackworth WA, Heuman DM, et al. Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int 2009;29(7):1071-1077.
  12. Kling CE, Perkins JD, et al. Recent trends in liver transplantation for alcoholic liver disease in the United States. World J Hepatol 2017;9(36):1315-1321.
  13. Forman LM, Lewis JD, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122(4):889-896.
  14. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008;14 Suppl 2:S36-544.
  15. Abdelqader A, Kabacam G, et al. Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved. Exp Clin Transplant 2017;15(Suppl 1):1-5.
  16. Curry MP, O'Leary JG, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015;373(27):2618-2628.
  17. Beinhardt S, Al-Zoairy R, et al. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver Int 2017.
  18. Lionetti R, Calvaruso V, et al. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. Clin Transplant 2018;32(2).
  19. Anand AC, Agarwal SK, et al. Sofosbuvir and Ribavirin for 24 Weeks Is An Effective Treatment Option for Recurrent Hepatitis C Infection After Living Donor Liver Transplantation. J Clin Exp Hepatol 2017;7(3):165-171.
  20. Townsend SA, Monga MA, et al. Hepatitis C Virus Recurrence Occurs Earlier in Patients Receiving Donation After Circulatory Death Liver Transplant Grafts Compared With Those Receiving Donation After Brainstem Death Grafts. Transplant Proc 2017;49(9):2129-2134.
  21. Niranjan-Azadi AM, Kabacam G, et al. Single-Center Experience in Pretransplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA). Ann Transplant 2017;22:570-574.
  22. Northup PG, Argo CK, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int 2010;23(10):1038- 1044.
  23. Levitsky J, Formica RN, et al. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2017;17(11):2790-2802.
  24. Saberi B, Hamilton JP, et al. Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipient. Liver Transpl 2018;24(1):140-143.
  25. Boyarsky BJ, Durand CM, et al. Challenges and Clinical Decision- Making in HIV-to-HIV Transplantation: Insights From the HIV Literature. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015;15(8):2023-2030.
  26. Gow PJ, Pillay D, et al. Solid organ transplantation in patients with HIV infection. Transplantation 2001;72(2):177-181.
  27. Roland ME, Stock PG. Review of solid-organ transplantation in HIVinfected patients. Transplantation 2003;75(4):425-429.
  28. Campos-Varela I, Dodge JL, et al. Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. Clin Transplant 2016;30(9):1140-1145.
  29. Roland ME, Barin B, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008;8(2): 355-365.
  30. Antonini TM, Coilly A, et al. Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study. Transplantation 2018;102(1):119-126.
  31. Ragni MV, Eghtesad B, et al. Pretransplant survival is shorter in HIVpositive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005;11(11):14251430.
  32. Pineda JA, Romero-Gomez M, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005;41(4):779-789.
  33. Subramanian A, Sulkowski M, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010;138(1):159-164.
  34. Muller E, Barday Z, et al. Renal transplantation between HIV-positive donors and recipients justified. S Afr Med J 2012;102(6):497-498.
  35. Carithers RL Jr, Herlong HF, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110(9):685-690.
  36. Maddrey WC, Boitnott JK, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75(2):193-199.
  37. Louvet A, Naveau S, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348-1354.
  38. Singal AK, Kamath PS, et al. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol 2014;12(4):555-564; quiz e531-552.
  39. Louvet A, Diaz E, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008;48(3):465-470.
  40. Dunn W, Jamil LH, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005;41(2):353-358.
  41. Lucey MR, Mathurin P, et al. Alcoholic hepatitis. N Engl J Med 2009;360(26):2758-2769.
  42. Dew MA, DiMartini AF, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008;14(2):159-172.
  43. Mathurin P, Moreno C, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365(19):1790-1800.
  44. Weeks SR, Sun Z, et al. Liver Transplantation for Severe Alcoholic Hepatitis, Updated Lessons from the World's Largest Series. J Am Coll Surg 2018;226(4):549-557.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.